Valuation: Aquestive Therapeutics, Inc.

Market Cap 47Cr 41Cr 38Cr 35Cr 66Cr 4.49TCr 67Cr 447.88Cr 175.77Cr 2.24TCr 176.89Cr 173.05Cr 7.46TCr P/E 2026 *
-9.68x
P/E 2027 * -10.1x
Enterprise Value 39Cr 34Cr 31Cr 29Cr 54Cr 3.68TCr 55Cr 367.07Cr 144.06Cr 1.84TCr 144.98Cr 141.83Cr 6.12TCr EV / Sales 2026 *
7.64x
EV / Sales 2027 * 6.55x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day+4.39%
1 week+5.38%
Current month+6.09%
1 month-7.55%
3 months-7.33%
6 months-4.62%
Current year-39.32%
1 week 3.65
Extreme 3.65
3.92
1 month 3.56
Extreme 3.56
4.36
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
09/03/26 Free

General Counsel

2,00,311 0.1642%
09/03/26 Other

Chief Operating Officer

1,68,291 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+4.39%+5.38%-1.75%+87.56% 47Cr
+1.89%+3.20%+59.70%+165.18% 1,04300Cr
-0.24%+0.45%+50.64%+52.02% 62TCr
-0.95%-5.26%+24.23%+65.08% 44TCr
0.00%+3.20%+46.70%+37.60% 36TCr
+0.58%-1.26%+35.52%+40.54% 29TCr
-1.55%-9.78%+5.61%+8.62% 25TCr
-0.73%+4.44%+42.22%+66.41% 22TCr
-0.24%-11.27%+1.42%-44.69% 20TCr
-0.68%-0.32%+18.66%+66.32% 16TCr
Average -0.03%-1.86%+28.30%+54.46% 35.9TCr
Weighted average by Cap. -0.54%-1.42%+40.55%+77.19%

Financials

2026 *2027 *
Net sales 5.05Cr 4.38Cr 4.1Cr 3.75Cr 7.09Cr 481.17Cr 7.18Cr 48Cr 19Cr 240.41Cr 19Cr 19Cr 800.18Cr 7.19Cr 6.24Cr 5.84Cr 5.35Cr 10Cr 685.07Cr 10Cr 68Cr 27Cr 342.28Cr 27Cr 26Cr 1.14TCr
Net income -5.06Cr -4.4Cr -4.12Cr -3.76Cr -7.11Cr -482.46Cr -7.2Cr -48Cr -19Cr -241.05Cr -19Cr -19Cr -802.32Cr -4.8Cr -4.16Cr -3.9Cr -3.57Cr -6.73Cr -457.19Cr -6.82Cr -46Cr -18Cr -228.43Cr -18Cr -18Cr -760.3Cr
Net Debt -8.5Cr -7.38Cr -6.91Cr -6.32Cr -12Cr -809.7Cr -12Cr -81Cr -32Cr -404.55Cr -32Cr -31Cr -1.35TCr -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
06/26/06 $3.920 +4.39% 15,32,468
05/26/05 $3.755 +0.40% 14,66,033
04/26/04 $3.740 -1.32% 26,91,743
03/26/03 $3.790 +2.57% 23,81,422
31/26/31 $3.695 -0.67% 17,85,710
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.920USD
Average target price
8.889USD
Spread / Average Target
+126.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock